Vitamin D, selenium, and antidiabetic drugs in the treatment of type 2 diabetes mellitus with Hashimoto's thyroiditis

doi:10.4239/wjd.v15.i2.209

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2647)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

WORD

HTML

1438

Figures (1-2)

Tables (1-6)

100

Sum=1686

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

225

Download

325

Sum=550

Publishing Process of This Article

Item

Count

Browse

127

Download

169

Sum=296

Feb 15, 2024 (publication date) through May 16, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Feb 15, 2024; 15(2): 209-219
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.209

Table 1 Comparison of general data among the three patient groups

Group	Sex (male/female)	Age (yr)	BMI (kg/m²)
Control group (n = 50)	23/27	53.78 ± 7.49	22.88 ± 2.31
Test group A (n = 50)	26/24	52.76 ± 7.88	23.07 ± 2.17
Test group B (n = 50)	22/28	52.52 ± 8.13	22.98 ± 2.30
χ²/F value	1.361	0.364	0.085
P value	0.715	0.695	0.918

BMI: Body mass index.

Table 2 Comparison of thyroid function pre-treatment and after 3 and 6 months of treatment in the three groups

Group	TSH (mU/L)			FT3 (pmol/L)			FT4 (pmol/L)
	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment
Control group (n = 50)	14.50 ± 2.30	13.29 ± 2.34	12.89 ± 2.18	2.39 ± 0.77	2.57 ± 0.83	2.65 ± 0.82	7.35 ± 1.35	8.27 ± 1.45	8.96 ± 2.05
Test group A (n = 50)	14.49 ± 2.23	8.37 ± 2.33^a	4.98 ± 1.45^a	2.43 ± 0.80	3.98 ± 0.86^a	5.21 ± 1.26^a	7.28 ± 1.38	11.27 ± 2.16^a	15.51 ± 2.40^a
Test group B (n = 50)	14.70 ± 2.34	8.54 ± 2.41^a^,^b	4.05 ± 1.27^a^,^b	2.48 ± 0.81	4.05 ± 0.90^a^,^b	5.47 ± 1.34^a^,^b	7.26 ± 1.26	11.87 ± 2.27^a^,^b	16.91 ± 2.73^a^,^b
F value	0.133	70.399	416.857	0.162	47.220	89.340	0.063	52.264	155.329
P value	0.875	< 0.001	< 0.001	0.850	< 0.001	< 0.001	0.939	< 0.001	< 0.001

^aP < 0.05 vs group pre-treatment.

^bP < 0.05 vs 3 months after treatment.

TSH: Thyroid-stimulating hormone; FT3: Free T3; FT4: Free T4

Table 3 Comparison of blood glucose index and blood lipid index pre-treatment, 3 months after treatment, and 6 months after treatment in 3 groups

Group	TC (mU/L)			TG (pmol/L)
Group	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment
Control group (n = 50)	5.13 ± 0.86	4.46 ± 0.81	4.16 ± 0.77	3.21 ± 1.02	2.97 ± 0.91	2.93 ± 0.91
Test group A (n = 50)	4.98 ± 0.89	3.76 ± 0.75^a	2.76 ± 0.68^a	3.17 ± 0.96	2.43 ± 0.71^a	1.98 ± 0.65^a
Test group B (n = 50)	4.96 ± 0.92	3.07 ± 0.68^a^,^b	2.40 ± 0.69^a^,^b	3.16 ± 1.05	2.08 ± 0.64^a^,^b	1.83 ± 0.60^a^,^b
F value	0.546	43.665	84.262	0.033	17.243	32.575
P value	0.581	< 0.001	< 0.001	0.967	< 0.001	< 0.001

^aP < 0.05 vs group pre-treatment.

^bP < 0.05 vs 3 months after treatment.

TC: Total cholesterol; TG: Triacylglycerol.

Table 4 Comparison of blood glucose index and blood lipid index pre-treatment, 3 months after treatment, and 6 months after treatment in 3 groups

Group	LDL-C (pmol/L)			FBG(pmol/L)			HbA1c(%)
Group	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment
Control group (n = 50)	1.31 ± 0.43	1.43 ± 0.44	1.48 ± 0.45	13.52 ± 3.35	13.46 ± 3.33	13.37 ± 3.28	9.16 ± 1.55	8.90 ± 1.35	7.65 ± 1.26
Test group A (n = 50)	1.34 ± 0.43	1.76 ± 0.46^a	2.18 ± 0.50^a	13.69 ± 3.76	12.34 ± 3.82^a	12.98 ± 2.98^a	8.98 ± 1.58	8.55 ± 1.30	7.09 ± 1.15^a^,^b
Test group B (n = 50)	1.33 ± 0.40	1.87 ± 0.48^a	2.41 ± 0.58^a^,^b	13.60 ± 3.80	9.64 ± 1.45^a	7.30 ± 1.48^a^,^b	9.35 ± 1.52	8.20 ± 1.2^a	6.45 ± 1.10^a^,^b
F value	0.067	11.717	44.330	0.031	20.859	49.495	0.712	3.603	13.130
P value	0.935	< 0.001	< 0.001	0.970	< 0.001	< 0.001	0.492	0.030	< 0.001

^aP < 0.05 vs group pre-treatment.

^bP < 0.05 vs 3 months after treatment.

LDL-C: Low-density lipoprotein cholesterol; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c.

Table 5 Correlations between serum 25-hydroxyvitamin D3 level and various indexes in test group A

Index	25 (OH) D₃
Index	r	P value
TSH	0.008	0.866
FT3	-0.027	0.853
FT4	-0.326	0.021
TPOAB	-0.017	0.905
TGAB	-0.322	0.021
TC	-0.041	0.776
TG	0.021	0.143
LDL-C	0.177	0.218
FBG	0.111	0.444
HbA1c	0.035	0.810

TSH: Thyroid-stimulating hormone; FT3: Free T3: FT4: Free T4; TPOAB: Thyroid peroxidase antibodies; TGAB: Thyroglobulin antibodies; TC: Total cholesterol; TG: Triacylglycerol; LDL-C: Low-density lipoprotein cholesterol; FBG: Fasting blood glucose; HbA1c: Hemoglobin a1c; 25 (OH) D₃: 25-hydroxyvitamin D3.

Table 6 Correlation between serum 25-hydroxyvitamin D3 level and various indexes in test group B

Index	25 (OH) D₃
Index	r	P value
TSH	-0.205	0.866
FT3	-0.069	0.633
FT4	-0.291	0.040
TPOAB	0.107	0.459
TGAB	-0.457	0.001
TC	0.003	0.985
TG	0.148	0.306
LDL-C	-0.025	0.861
FBG	0.079	0.587
HbA1c	0.230	0.108

TSH: Thyroid-stimulating hormone; FT3: Free T3: FT4: Free T4; TPOAB: Thyroid peroxidase antibodies; TGAB: Thyroglobulin antibodies; TC: Total cholesterol; TG: Triacylglycerol; LDL-C: Low-density lipoprotein-cholesterol; FBG: Fasting blood glucose; HbA1c: Hemoglobin a1c; 25 (OH) D₃: 25-hydroxyvitamin D3.

Citation: Feng F, Zhou B, Zhou CL, Huang P, Wang G, Yao K. Vitamin D, selenium, and antidiabetic drugs in the treatment of type 2 diabetes mellitus with Hashimoto's thyroiditis. World J Diabetes 2024; 15(2): 209-219
URL: https://www.wjgnet.com/1948-9358/full/v15/i2/209.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i2.209